drugset / Trial / NCT01155284

Combination Therapy With Sitagliptin and Lansoprazole to Restore Pancreatic Beta Cell Function in Recent-Onset Type 1 Diabetes

NCT01155284

RandomizedParallel-groupTriple-blindTreatment

Summary

Sanford Research/USD proposes to study the combination therapy of oral administration of sitagliptin and lansoprazole versus placebo for the preservation of pancreatic beta cells still present in patients with recent-onset diabetes and possibly regenerating their beta cells, while safely down-regulating the autoimmune response directed against the beta cells.

Timeline

Start
2010-08
Primary completion
2014-05
Completion
2015-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Lansoprazole Other / unclassified 30 mg Oral
Subject Lansoprazole Other / unclassified 60 mg Oral
Subject Sitagliptin Small molecule 50 mg Oral
Subject Sitagliptin Small molecule 100 mg Oral